tadalafil teva 5 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - tadalafilum - tabletki powlekane - 5 mg
tadalafil teva 20 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - tadalafilum - tabletki powlekane - 20 mg
tadalafil aristo 20 mg tabletki powlekane
aristo pharma sp. z o.o. - tadalafilum - tabletki powlekane - 20 mg
tadalafil mensil 10 mg tabletki powlekane
przedsiębiorstwo produkcji farmaceutycznej hasco-lek s.a. - tadalafilum - tabletki powlekane - 10 mg
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - chlorowodorek klopidogrelu - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - Środki przeciwzakrzepowe - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
clopidogrel sandoz
acino pharma gmbh - klopidogrel - peripheral vascular diseases; stroke; myocardial infarction - Środki przeciwzakrzepowe - klopidogrel wskazany jest u dorosłych do zapobiegania zdarzeniom w: * pacjentów z zawałem mięśnia sercowego (od kilku dni do mniej niż 35 dni), niedokrwiennym (od 7 dni do mniej niż 6 miesięcy) lub siedzibę obwodowa chorobą tętnic. aby uzyskać więcej informacji, proszę odnieść się do rozdziału 5.
finasterid stada 5 mg tabletki powlekane 5 mg tabletki powlekane
stada arzneimittel ag - finasteridum - tabletki powlekane - 5 mg
latanoprost stada 50 mcg/ml krople do oczu, roztwór
stada arzneimittel ag - latanoprostum - krople do oczu, roztwór - 50 mcg/ml
orlistat stada 60 mg 60 mg kapsułki twarde
stada arzneimittel ag - orlistat - kapsułki twarde - 60 mg
ibandronic acid stada 150 mg tabletki powlekane
stada arzneimittel ag - natrii ibandronas monohydricum - tabletki powlekane - 150 mg